To view this email as a web page, click here.
July 25, 2019
 
ACC/AHA Updates CVD Prevention Guidelines
Eighty percent of all cardiovascular events are preventable. Review the ACC/AHA 2019 primary prevention guidelines that will help achieve that goal.

Read more
 
Three New Studies in Cardioprotection
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in 3 studies showcased at ACC.19.

Read more
 
Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials
Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.

Read more
 
ARRIVE, ASCEND, and the Future of Aspirin
The future role of aspirin in primary prevention of cardiovascular disease is unclear, and not for lack of scrutiny. Get highlights of 2 pivotal studies.

Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.